ILiAD Biotechnologies

ILiAD Biotechnologies (ILiAD) is a clinical-stage biotechnology company focused on the prevention and treatment of disease caused by Bordetella Pertussis. ILiAD's lead candidate is BPZE1, a live-attenuated pertussis vaccine that has successfully completed a Phase 1 human clinical trial.

ILiAD Biotechnologies is a registered Delaware company founded in 2012.

ILiAD Biotechnologies headquartered in New York, New York, United States, North America, operates in the Biotechnology, Health Care, Pharmaceutical, Clinical Trials sector. The company focuses on Biotechnology and has secured $6.2B in funding across 96 round(s). With a team of 11-50 employees, ILiAD Biotechnologies is actively contributing to advancements in Biotechnology. Their latest funding round, Debt Financing - ILiAD Biotechnologies, raised $640.0K. Discover more about their projects, partnerships, and impact on our platform.